63
Participants
Start Date
June 17, 2021
Primary Completion Date
October 17, 2023
Study Completion Date
October 17, 2023
Tislelizumab
200 mg intravenously every three weeks
Durvalumab
10 milligrams per kilogram (mg/kg) intravenously once every 2 weeks (or 1500 mg intravenously once every 4 weeks where the dosage has been approved by a local health authority)
Ociperlimab
900 milligrams (mg) intravenously every three weeks
Chemotherapy
"The chemotherapy regimen for the study treatment was selected at the investigator's discretion and may include one of the following options:~* Cisplatin (50 mg/m²) on days 1 to 5 of each cycle, combined with etoposide (50 mg/m²) on days 1 and 8, both administered intravenously for 2 cycles. Each cycle was 28 days.~* Carboplatin (AUC 2) weekly for 6 weeks, combined with paclitaxel (40-50 mg/m²) weekly for 6 weeks, both administered intravenously.~* Cisplatin (75 mg/m²) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~* Carboplatin (AUC 5) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~The pemetrexed plus platinum regimen was only for participants with non-squamous histology."
Radiotherapy
All participants recieved radiotherapy using either a standardized 3-dimensional conformal radiotherapy technique, or intensity modulated radiotherapy (IMRT) on a linear accelerator delivering a beam energy of ≥ 6 MV. The total dose of radiotherapy was 60 Gy, administered in 30 once-daily fractions of 2 Gy and 5 fractions per week for 6 weeks.
Cabrini Hospital, Malvern
Gold Coast University Hospital, Gold Coast
Townsville Hospital, Douglas
Lyell McEwin Hospital, Elizabeth Vale
Taipei Veterans General Hospital, Taipei
Ico Girona, Girona
Hospital Universitario Fundación Jiménez Díaz, Alcorcón
Chung Shan Medical University Hospital, Taichung
Changhua Christian Hospital, Changhua
XCancer/Centeral Care Center, Bolivar
Beijing Cancer Hospital, Beijing
Jilin Cancer Hospital, Changchun
The First Hospital of Jilin University, Changchun
Fudan University Shanghai Cancer Center, Shanghai
Nanjing First Hospital, Nanjing
Changzhou Cancer Hospital, Changzhou
The First Affiliated Hospital of Soochow University Branch Shizi, Suzhou
Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang
Fujian Cancer Hospital, Fuzhou
Chongqing University Cancer Hospital, Chongqing
Hunan Cancer Hospital - GCP Office, Changsha
Nanfang Hospital of Southern Medical University, Guangzhou
Jieyang People'S Hospital (Jieyang Affiliated Hospital, Sun Yat-Sen University ), Jieyang
West China Hospital, Sichuan University, Chengdu
General Hospital of Ningxia Medical University, Yinchuan
Southern Medical Day Care Centre, Wollongong
Royal Hobart Hospital, Hobart
Hollywood Private Hospital, Perth
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
Peking University Third Hospital, Beijing
Taichung Veterans General Hospital, Taichung
Instituto Oncologico Dr. Rosell, Barcelona
Lead Sponsor
BeiGene
INDUSTRY